Data Sheet 1_PRELP-associated transcriptomic remodeling links alternative splicing and immune checkpoint blockade outcome in melanoma.pdf

The extracellular matrix protein proline/arginine-rich end leucine-rich repeat protein (PRELP), an extracellular matrix protein, contributes to stromal architecture and tumor–immune interactions. This study investigated whether PRELP expression drives transcriptomic remodeling, alternative splicing, interferon (IFN)-related signaling pathways to influence immunotherapy responsiveness in melanoma.</p>Methods<p>Bulk RNA sequencing was performed on PRELP-high and PRELP-low BUF1088 melanoma cells to assess differential gene expression and alternative splicing landscapes.

Downstream pathway changes were characterized using hallmark enrichment analysis. The translational relevance of the profiles was assessed using publicly available single-cell RNA sequencing datasets and clinical melanoma ICB cohorts.</p>Results<p>Differential splicing analysis identified 274 significant splicing events across 230 genes, predominantly exon skipping events. Key differentially spliced genes included AAR2, SACM1L, CD22, ACTB, MYO5A, WARS1, BTN3A3, IL24, and HNRNPA3.